BrainXell, Inc.

BrainXell provides iPSC-derived human neurons to the pharmaceutical industry and other research organizations for CNS drug discovery and development. Utilizing proprietary technology developed over the last two decades by Professor Su-Chun Zhang at the University of Wisconsin-Madison, we generate high-purity, subtype-specific neurons that rapidly mature. Multiple neuron subtypes relevant to a range of disorders are available. Additionally, any of these neurons can be made in custom batches from 50 million to 10 billion neurons from iPSC or ESC lines selected by the customer.

Publications

• Du ZW et al. (2015) Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 6:6626.
  
• Chen et al. (2014) Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 14(6):796-809.
  
• Liu et al. (2015) Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability. Sci Rep. 5:12189.
  
• Xi J et al. (2012) Specification of Midbrain Dopamine Neurons from Primate Pluripotent Stem Cells. Stem Cells. 30(8):1655-63.
  
• Chen Y et al. (2016) Chemical Control of Grafted Human PSC-Derived Neurons in a Mouse Model of Parkinson's Disease. Cell Stem Cell. 18(6):817-26.
  
• Johnson MA et al. (2007) Functional Neural Development from Human Embryonic Stem Cells: Accelerated Synaptic Activity Via Astrocyte Coculture. J Neurosci. 27(12):3069-77.
  
• Weick JP et al. (2011) Human embryonic stem cell-derived neurons adopt and regulate the activity of an established neural network. Proc Natl Acad Sci U S A. 108(50):20189-94.
  
• Liu et al. (2013) Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. Nat Protoc. 8(9):1670-9.